Primary Hepatobiliary Cancer Cohort of Central China
Launched by TONGJI HOSPITAL · Aug 28, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Primary Hepatobiliary Cancer Cohort of Central China, is studying patients who have been diagnosed with liver cancer or biliary tumors at Tongji Hospital in Wuhan. The goal of the study is to gather important information about the clinical characteristics of these cancers and to track how patients are doing after receiving various treatments, especially surgical options, since 1998.
To be eligible for this study, participants need to be at least 18 years old, have a life expectancy of at least six months, and have a confirmed diagnosis of primary liver cancer or a biliary tumor. They should also have at least one measurable tumor that can be evaluated. The study is currently looking for volunteers, and those who join can expect to provide their health information and possibly receive additional monitoring and support. It's important to know that patients with certain conditions, like not having measurable tumors or having multiple primary cancers, may not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. ≥18 years old,
- • 2. life expectancy is at least 6 months.
- • 3. Diagnosed as primary liver cancer or biliary malignant tumor by histopathology or confirmed by imaging as HCC (by the AASLD or guidance for the diagnosis and treatment of primary liver cancer of China (version 2022).
- • 4. At least one measurable lesion (RECIST v1.1)
- • 5. Subjects volunteer to participate in the study and sign informed consent.
- Exclusion Criteria:
- Patients with one or more of the following criteria should be excluded:
- • 1. CT or MRI shows no measurable lesions (RECIST v1.1).
- • 2. Patients after comprehensive assessment are considered by the investigators to be unsuitable for participating in the study.
- • 3. Incomplete baseline or follow-up data
- • 4. Suffering from more than two kinds of primary tumors
About Tongji Hospital
Tongji Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology, is a leading medical institution in China dedicated to advancing healthcare through innovative research and clinical trials. With a robust infrastructure and a multidisciplinary team of experts, Tongji Hospital focuses on translating scientific discoveries into effective treatments and therapies. The hospital is committed to enhancing patient care by conducting rigorous clinical trials that adhere to the highest ethical and regulatory standards, fostering collaboration with both national and international research communities to drive medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Bixiang Zhang
Study Chair
Tongji Hospital
Zeyang Ding
Principal Investigator
Tongji Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials